- Home
- NCV vs NGNE Comparison
NCV vs NGNE Comparison
Compare NCV & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- NGNE
- Stock Information
- Founded
- NCV 2003
- NGNE 2003
- Country
- NCV United States
- NGNE United States
- Employees
- NCV N/A
- NGNE N/A
- Industry
- NCV Finance Companies
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- NCV Finance
- NGNE Health Care
- Exchange
- NCV Nasdaq
- NGNE Nasdaq
- Market Cap
- NCV 326.0M
- NGNE 325.3M
- IPO Year
- NCV N/A
- NGNE N/A
- Fundamental
- Price
- NCV $14.75
- NGNE $18.48
- Analyst Decision
- NCV
- NGNE Strong Buy
- Analyst Count
- NCV 0
- NGNE 7
- Target Price
- NCV N/A
- NGNE $41.86
- AVG Volume (30 Days)
- NCV 405.1K
- NGNE 110.1K
- Earning Date
- NCV 01-01-0001
- NGNE 08-11-2025
- Dividend Yield
- NCV 12.48%
- NGNE N/A
- EPS Growth
- NCV N/A
- NGNE N/A
- EPS
- NCV N/A
- NGNE N/A
- Revenue
- NCV N/A
- NGNE N/A
- Revenue This Year
- NCV N/A
- NGNE N/A
- Revenue Next Year
- NCV N/A
- NGNE N/A
- P/E Ratio
- NCV N/A
- NGNE N/A
- Revenue Growth
- NCV N/A
- NGNE N/A
- 52 Week Low
- NCV $2.84
- NGNE $6.88
- 52 Week High
- NCV $3.59
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- NCV 66.05
- NGNE 35.93
- Support Level
- NCV $14.27
- NGNE $19.59
- Resistance Level
- NCV $14.78
- NGNE $20.46
- Average True Range (ATR)
- NCV 0.14
- NGNE 1.23
- MACD
- NCV 0.01
- NGNE -0.20
- Stochastic Oscillator
- NCV 90.57
- NGNE 13.37
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.